Andrew Aromando insider trades
Open-market stock purchases and sales by Andrew Aromando, Chief Business Officer at Oncolytics Biotech Inc, from SEC Form 4 filings since Apr 28, 2023.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -42%.